Form 4: BioVie Inc. Director Michael Sherman Acquires Stock Options
SEC Form 4 Filing
BioVie Inc. director Michael Sherman has acquired stock options in two separate transactions, according to a recent SEC filing.
Summary
- Michael Sherman, a director at BioVie Inc., has reported the acquisition of stock options.
- On November 20, 2024, Sherman acquired options to purchase 56,900 shares of common stock at an exercise price of $3.36 per share.
- These options vest in four equal installments starting February 8, 2025, and ending no later than November 8, 2025.
- On December 20, 2024, Sherman acquired additional options to purchase 23,325 shares of common stock at an exercise price of $1.90 per share.
- These options vest in three equal installments starting December 20, 2024, and ending December 20, 2026.
- Both sets of options expire five years from their respective grant dates.
Sentiment
Score: 6
Explanation: The document is neutral in sentiment, as it simply reports a standard insider transaction. It is neither particularly positive nor negative for the company's prospects.
Positives
- The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future performance.
- The vesting schedules of the options may incentivize the director to contribute to the company's long-term success.
Risks
- The value of the options is dependent on the future performance of BioVie's stock price.
- There is no guarantee that the stock price will rise above the exercise price, making the options potentially worthless.
Future Outlook
The document does not contain any forward-looking statements or guidance.
Industry Context
This is a standard SEC filing for insider transactions and is common practice for publicly traded companies. It provides transparency into the compensation and ownership structure of the company.
Comparison to Industry Standards
- Stock option grants are a common form of compensation for directors and executives in publicly traded companies.
- The vesting schedules and exercise prices are typical for such grants, designed to align the interests of the director with those of the shareholders.
- Companies like Amgen, Gilead, and Regeneron also use stock options as part of their compensation packages for directors and executives.
Stakeholder Impact
- The stock option grants may have a minor positive impact on shareholder sentiment, as it indicates director confidence in the company.
- The grants do not have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 11/20/2024 | Date of the first stock option grant for 56,900 shares at $3.36. |
| 12/20/2024 | Date of the second stock option grant for 23,325 shares at $1.90. |
| 01/07/2025 | Date of filing of the SEC Form 4. |
| 02/08/2025 | First vesting date for the 56,900 share options. |
| 05/08/2025 | Second vesting date for the 56,900 share options. |
| 08/08/2025 | Third vesting date for the 56,900 share options. |
| 11/08/2025 | Final vesting date for the 56,900 share options, or the date of the 2025 annual shareholders' meeting, whichever is earlier. |
| 12/20/2025 | Second vesting date for the 23,325 share options. |
| 12/20/2026 | Final vesting date for the 23,325 share options. |
| 11/20/2029 | Expiration date for the 56,900 share options. |
| 12/20/2029 | Expiration date for the 23,325 share options. |
Keywords
stock options, insider trading, SEC Form 4, BioVie Inc., Michael Sherman, equity, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.